GlassScriptPhysician profile
Nicole Allison Carson
NPI 1023086089
$5,023.22
in general payments reported to CMS, 2019-2025
28 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $637 · 2022: $1,128 · 2023: $1,139 · 2024: $1,024 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,241 · Education: $17.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,241.33 |
| Education | $17.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.31 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $534.59 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $480.25 | 2021-2022 | |
| Harmony Biosciences LLC | $394.02 | 2022-2023 | Wakix |
| Janssen Pharmaceuticals, INC | $338.76 | 2021-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $277.73 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $272.06 | 2023-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $213.60 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $194.45 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.99 | 2021-2025 | Caplyta |
| Tris Pharma INC | $158.87 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Lundbeck LLC | $152.52 | 2021-2025 | Abilify Asimtufii, Rexulti |
| Corium, LLC | $148.13 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $123.70 | 2021-2024 | Trintellix |
| Almatica Pharma LLC | $85.01 | 2023-2025 | Loreev Xr, Sertraline Hcl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $82.20 | 2024-2025 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $76.26 | 2022-2025 | Qelbree |
| Indivior INC. | $70.54 | 2022-2023 | Perseris |
| Axsome Therapeutics, INC. | $58.25 | 2025 | Auvelity, Sunosi |
| Eisai INC. | $56.81 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $53.85 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $53.50 | 2024-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $36.84 | 2025 | Cobenfy |
| Boston Scientific Corporation | $24.61 | 2022 | |
| Collegium Pharmaceutical, INC. | $22.72 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $17.62 | 2024 | |
| Merck Sharp & Dohme LLC | $16.67 | 2023 | Belsomra |
| Currax Pharmaceuticals LLC | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.